Kraj: Australia
Język: angielski
Źródło: Department of Health (Therapeutic Goods Administration)
ciprofloxacin
Alphapharm Pty Ltd
Ciprofloxacin
Registered
CIPROFLOXACIN ALPHAPHARM _ciprofloxacin_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about CIPROFLOXACIN ALPHAPHARM. It does not contain all the available information. It does not take the place of talking to your doctor or your pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking CIPROFLOXACIN ALPHAPHARM against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT CIPROFLOXACIN ALPHAPHARM IS USED FOR CIPROFLOXACIN ALPHAPHARM is used to treat serious infections in the lungs, skin, blood, bone and joints, kidneys and bowel. CIPROFLOXACIN ALPHAPHARM is also used to treat inhalational anthrax (an infection caused by breathing in the spores of bacteria). CIPROFLOXACIN ALPHAPHARM contains the drug ciprofloxacin, which is an antibiotic belonging to a group of medicines called quinolones (pronounced kwin- o-lones). These antibiotics work by killing the bacteria which cause infections in the body. CIPROFLOXACIN ALPHAPHARM is used in hospitalised patients where the use of ciprofloxacin tablets is inappropriate. CIPROFLOXACIN ALPHAPHARM will not work against infections caused by viruses such as colds or the flu. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another reason. BEFORE YOU ARE GIVEN CIPROFLOXACIN ALPHAPHARM _WHEN YOU MUST NOT BE GIVEN_ _IT_ YOU MUST NOT BE GIVEN CIPROFLOXACIN ALPHAPHARM IF YOU HAVE AN ALLERGY TO: • ciprofloxacin • other quinolone antibiotics including nalidixic acid, moxifloxacin, norfloxacin • any of the ingredients listed at the end of this leaflet Some of the symptoms of an allergic reaction may include: • shortness of breath • wheezing or difficulty breathing • swelling of the face, lips, tongue or other parts of the body • skin rash, itching or Przeczytaj cały dokument
AUSTRALIAN PRODUCT INFORMATION CIPROFLOXACIN ALPHAPHARM _ciprofloxacin intravenous infusion injection _ 1 NAME OF THE MEDICINE Ciprofloxacin 2 QUALITATIVE AND QUANTITATIVE COMPOSITION CIPROFLOXACIN ALPHAPHARM is available as a ciprofloxacin (as lactate) 200 mg/100 mL and 400 mg/200 mL infusion solution. Each intravenous infusion injection bag contains 200 mg in 100 mL or 400 mg in 200 mL of ciprofloxacin as the active ingredient. Excipient with known effect: glucose For the full list of excipients, see section 6.1 List of Excipients. 3 PHARMACEUTICAL FORM The solution is a clear, colourless to a slightly yellowish solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS CIPROFLOXACIN ALPHAPHARM is indicated for use in the following: • Use in hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate • Treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems: lower respiratory tract infections (Gram negative organisms); skin and skin structure; septicaemia; bone and joint; urinary tract • Inhalational anthrax (post-exposure). To reduce the incidence or progression of disease following exposure to aerosolised _Bacillus anthracis_ . Ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication Note: because Gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with Gram-positive infections due to _Strep pneumoniae_ . If anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. Strains of _N gonorrhoeae_ resistant to ciprofloxacin have been reported in Australia. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to cipro Przeczytaj cały dokument